These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 21352789)

  • 1. Re-assessment of mitigation strategies for deliberate releases of anthrax using a real-time outbreak characterization tool.
    Egan JR; Legrand J; Hall IM; Cauchemez S; Ferguson NM; Leach S
    Epidemics; 2010 Dec; 2(4):189-94. PubMed ID: 21352789
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Public health vaccination policies for containing an anthrax outbreak.
    Brookmeyer R; Johnson E; Bollinger R
    Nature; 2004 Dec; 432(7019):901-4. PubMed ID: 15602561
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prevention of inhalational anthrax in the U.S. outbreak.
    Brookmeyer R; Blades N
    Science; 2002 Mar; 295(5561):1861. PubMed ID: 11884746
    [No Abstract]   [Full Text] [Related]  

  • 4. Responding to a small-scale bioterrorist anthrax attack: cost-effectiveness analysis comparing preattack vaccination with postattack antibiotic treatment and vaccination.
    Schmitt B; Dobrez D; Parada JP; Kyriacou DN; Golub RM; Sharma R; Bennett C
    Arch Intern Med; 2007 Apr; 167(7):655-62. PubMed ID: 17420423
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bichat guidelines for the clinical management of anthrax and bioterrorism-related anthrax.
    Bossi P; Tegnell A; Baka A; Van Loock F; Hendriks J; Werner A; Maidhof H; Gouvras G;
    Euro Surveill; 2004 Dec; 9(12):E3-4. PubMed ID: 15677848
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Preparedness for an anthrax attack.
    Franz DR
    Mol Aspects Med; 2009 Dec; 30(6):503-10. PubMed ID: 19619577
    [TBL] [Abstract][Full Text] [Related]  

  • 7. No evidence of a mild form of inhalational Bacillus anthracis infection during a bioterrorism-related inhalational anthrax outbreak in Washington, D.C., in 2001.
    Baggett HC; Rhodes JC; Fridkin SK; Quinn CP; Hageman JC; Friedman CR; Dykewicz CA; Semenova VA; Romero-Steiner S; Elie CM; Jernigan JA
    Clin Infect Dis; 2005 Oct; 41(7):991-7. PubMed ID: 16142664
    [TBL] [Abstract][Full Text] [Related]  

  • 8. An overview of adverse events reported by participants in CDC's anthrax vaccine and antimicrobial availability program.
    Martin SW; Tierney BC; Aranas A; Rosenstein NE; Franzke LH; Apicella L; Marano N; McNeil MM
    Pharmacoepidemiol Drug Saf; 2005 Jun; 14(6):393-401. PubMed ID: 15717323
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Modeling the logistics of response to anthrax bioterrorism.
    Zaric GS; Bravata DM; Cleophas Holty JE; McDonald KM; Owens DK; Brandeau ML
    Med Decis Making; 2008; 28(3):332-50. PubMed ID: 18349432
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Estimating the location and spatial extent of a covert anthrax release.
    Legrand J; Egan JR; Hall IM; Cauchemez S; Leach S; Ferguson NM
    PLoS Comput Biol; 2009 Jan; 5(1):e1000356. PubMed ID: 19360099
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cost-effectiveness comparison of response strategies to a large-scale anthrax attack on the chicago metropolitan area: impact of timing and surge capacity.
    Kyriacou DN; Dobrez D; Parada JP; Steinberg JM; Kahn A; Bennett CL; Schmitt BP
    Biosecur Bioterror; 2012 Sep; 10(3):264-79. PubMed ID: 22845046
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluation of public health interventions for Anthrax: a report to the secretary's council on Public Health Preparedness.
    Wein LM; Craft DL;
    Biosecur Bioterror; 2005; 3(4):348-56. PubMed ID: 16366844
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Modeling the optimum duration of antibiotic prophylaxis in an anthrax outbreak.
    Brookmeyer R; Johnson E; Bollinger R
    Proc Natl Acad Sci U S A; 2003 Aug; 100(17):10129-32. PubMed ID: 12890865
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Management of anthrax.
    Bartlett JG; Inglesby TV; Borio L
    Clin Infect Dis; 2002 Oct; 35(7):851-8. PubMed ID: 12228822
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Updated recommendations for antimicrobial prophylaxis among asymptomatic pregnant women after exposure to Bacillus anthracis.
    Centers for Disease Control and Prevention (CDC)
    MMWR Morb Mortal Wkly Rep; 2001 Nov; 50(43):960. PubMed ID: 11708594
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A Bayesian approach for estimating bioterror attacks from patient data.
    Ray J; Marzouk YM; Najm HN
    Stat Med; 2011 Jan; 30(2):101-26. PubMed ID: 20963771
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Vaccines: countering anthrax: vaccines and immunoglobulins.
    Grabenstein JD
    Clin Infect Dis; 2008 Jan; 46(1):129-36. PubMed ID: 18171228
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Predicting hospital surge after a large-scale anthrax attack: a model-based analysis of CDC's cities readiness initiative prophylaxis recommendations.
    Hupert N; Wattson D; Cuomo J; Hollingsworth E; Neukermans K; Xiong W
    Med Decis Making; 2009; 29(4):424-37. PubMed ID: 19617582
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bioterrorism. Implications for the occupational and environmental health nurse.
    Gwerder LJ; Beaton R; Daniell W
    AAOHN J; 2001 Nov; 49(11):512-8. PubMed ID: 11760706
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Public response to an anthrax attack: reactions to mass prophylaxis in a scenario involving inhalation anthrax from an unidentified source.
    SteelFisher G; Blendon R; Ross LJ; Collins BC; Ben-Porath EN; Bekheit MM; Mailhot JR
    Biosecur Bioterror; 2011 Sep; 9(3):239-50. PubMed ID: 21819225
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.